• bioAffinity Technologies posted Q1 2026 revenue down 27% to USD 1.4 million.
• Net loss widened to USD 3.6 million, or USD 0.81 per share.
• CyPath Lung testing revenue rose 114% to USD 361,000, while CyPath Lung unit sales climbed 146% year over year.
• Operating expenses increased to USD 5 million from USD 4.5 million, driven by selling, general and administrative costs rising to USD 3.2 million from USD 2.5 million.
• Launched a Department of Defense-backed longitudinal CyPath Lung trial expected to include up to 20 clinical sites; management said 2026 focus remains scaling commercialization, expanding into new geographic markets, and driving higher utilization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. bioAffinity Technologies Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260508460240) on May 08, 2026, and is solely responsible for the information contained therein.